Nifty Pharma Index: Today's Price, Returns, and Sector News
The Nifty Pharma Index, a key benchmark for the pharmaceutical sector on the National Stock Exchange (NSE), is a crucial indicator for investors tracking both defensive plays and growth opportunities in the healthcare space. The index comprises the top 20 pharmaceutical companies, reflecting the industry's overall health. This article covers the latest Nifty Pharma share price, its historical returns, and the news shaping the sector.
Today's Nifty Pharma Price
As of the market close on 4th June 2025, the Nifty Pharma Index stood at Rs. 21,371.70, posting a gain of 0.08% for the day.
For the most current, regularly updated Nifty Pharma share price, please refer to the Nifty Pharma index live ticker section located above on this page. That section provides a real-time share price summary, including the top gainer and loser stocks daily.
Nifty Pharma Historical Returns
The historical performance of the Nifty Pharma Index showcases its characteristic resilience and long-term growth potential. The returns as of early June 2025 are as follows:
- 1 Week: 0.04%
- 1 Month: -1.08%
- 3 Months: 6.14%
- 6 Months: -3.59%
- 1 Year: 13.03%
The Nifty Pharma today reflects a market that has delivered solid returns over the past year and has seen positive momentum over the last quarter. While the short-term one-month and six-month figures indicate a period of consolidation or correction, the strong annual return of over 13% highlights the sector's defensive appeal and ability to generate long-term value for investors in the India stock market.
Nifty Pharma News and Updates
The pharmaceutical sector was in the spotlight on Wednesday, 4th June 2025, with several key developments influencing the index. While the index itself closed with marginal gains, there was significant stock-specific action. Among the top performers from the Nifty Pharma stocks list were Gland Pharma, which surged over 2%, and Divi's Laboratories, which gained nearly 1.5%.
A major news event impacting the sector was the sharp fall in the share price of Sun Pharma Advanced Research Company (SPARC). The stock tumbled nearly 20% after its parent, Sun Pharma, announced the discontinuation of the development of a key drug, Vibozilimod, for psoriasis due to poor results in Phase 2 trials. This development highlights the inherent risks in pharmaceutical research and its direct impact on company valuations.
Overall, the pharma sector is often seen as a safe haven during times of market volatility. With the broader market showing some choppiness ahead of the RBI's monetary policy decision, defensive sectors like pharma are attracting investor interest. USFDA updates, new drug approvals, and global healthcare trends remain the primary long-term factors affecting the Nifty Pharma Index.